In Vitro and In Vivo 1H-MR Spectroscopic Examination of the Renal Cell Carcinoma

Background: Paraneoplastic effects are some of the major side effects of advanced renal cell carcinoma (RCC). Magnetic resonance spectroscopy (MRS) is known as a powerful tool to study cancer cell metabolism and cancer cell – host interactions. Aim of this study was to assess tumor cell metabolism and systemic effects using 1H-MRS. Methods: Spectroscopic analysis of 10 patients with RCC was compared with those of 15 healthy volunteers. Local tumor metabolism was assessed using image-guided 1H-in-vivo-spectroscopy in a 1.5 Tesla MR whole body tomograph. Systemic effects of RCC were measured using 1H-High-Resolution (HR) spectra of blood plasma samples in a 500 MHz Bruker DRX 500 spectrometer. Results: In-vivo-spectroscopy can significantly differentiate tumor tissue from healthy renal tissue by comparing their lipid composition. Moreover after detailed assignment of the various metabolites in blood plasma in the in-vitro-HR-spectra significant systemic alterations could be identified in patients with RCC especially regarding lipid and amino acid metabolism. Conclusion: This work indicates that using 1H-MRS both changes in tumor metabolism and resulting systemic/paraneoplastic effects can be assessed in patients with RCC. This approach therefore offers scope for diagnosis and therapy evaluation.

[1]  J. Jolles,et al.  Age dependence of plasma phospholipid fatty acid levels: potential role of linoleic acid in the age-associated increase in docosahexaenoic acid and eicosapentaenoic acid concentrations , 2009, British Journal of Nutrition.

[2]  U. Engelmann,et al.  31P NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma , 2002, NMR in biomedicine.

[3]  I. Smith,et al.  Magnetic resonance spectroscopy in medicine: clinical impact , 2002 .

[4]  N. Yoshioka,et al.  Evaluation of renal function with 99mTc-MAG3 using semiautomated regions of interest. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  A. R. Tate,et al.  Distinction between normal and renal cell carcinoma kidney cortical biopsy samples using pattern recognition of 1H magic angle spinning (MAS) NMR spectra , 2000, NMR in biomedicine.

[6]  C. Léger,et al.  Differences between polyunsaturated fatty acid status of non-institutionalised elderly women and younger controls: a bioconversion defect can be suspected , 1999, European Journal of Clinical Nutrition.

[7]  J C Lindon,et al.  Biochemical classification of kidney carcinoma biopsy samples using magic-angle-spinning 1H nuclear magnetic resonance spectroscopy. , 1998, Journal of pharmaceutical and biomedical analysis.

[8]  J. K. Kim,et al.  Localized in vivo proton spectroscopy of renal cell carcinoma in human kidney. , 1998, Journal of Korean medical science.

[9]  M. Kuliszkiewicz-Janus,et al.  Treatment-induced changes in 31P-MRS (magnetic resonance spectroscopy) spectra of sera from patients with acute leukemia. , 1997, Biochimica et biophysica acta.

[10]  Rudolph Willem,et al.  A computational strategy for the deconvolution of NMR spectra with multiplet structures and constraints: Analysis of overlapping 13C‐2H multiplets of 13C enriched metabolites from cell suspensions incubated in deuterated media , 1996, Magnetic resonance in medicine.

[11]  J. D. de Certaines,et al.  Magnetic resonance spectroscopy in cancer: phospholipid, neutral lipid and lipoprotein metabolism and function. , 1996, Anticancer research.

[12]  M. Kuliszkiewicz-Janus,et al.  Application of 31P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non-haematological cancers. , 1996, Anticancer research.

[13]  T. Engan.  Magnetic resonance spectroscopy of blood plasma lipoproteins in malignant disease: methodological aspects and clinical relevance. , 1996, Anticancer research.

[14]  M. Kuliszkiewicz-Janus,et al.  Application of 31P NMR spectroscopy to monitor chemotherapy‐associated changes of serum phospholipids in patients with malignant lymphomas , 1996, Magnetic resonance in medicine.

[15]  M. Rudling,et al.  Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma. , 1996, Biochimica et biophysica acta.

[16]  M. Kuliszkiewicz-Janus,et al.  Chemotherapy‐associated changes in 31P MRS spectra of sera from patients with multiple myeloma , 1995, NMR in biomedicine.

[17]  M. Spraul,et al.  750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. , 1995, Analytical chemistry.

[18]  M. Dietlein,et al.  Systemic alterations in phospholipid concentrations of blood plasma in patients with thyroid carcinoma: an in‐vitro 31P high‐resolution NMR study , 1995, NMR in biomedicine.

[19]  S. Gasa,et al.  Sulfolipids and glycolipid sulfotransferase activities in human renal cell carcinoma cells. , 1993, British Journal of Cancer.

[20]  J. Ruíz-Cabello,et al.  Phospholipid metabolites as indicators of cancer cell function , 1992, NMR in biomedicine.

[21]  T. Koyanagi,et al.  Presence and characterization of glycolipid sulfotransferase in human cancer serum. , 1990, European journal of biochemistry.

[22]  G. Murphy,et al.  Paraneoplastic and serologic syndromes of renal adenocarcinoma. , 1989, Seminars in urology.

[23]  T. Koyanagi,et al.  Association of elevated sulfatides and sulfotransferase activities with human renal cell carcinoma. , 1989, Cancer research.

[24]  R. Clayman,et al.  Abnormal cholesterol metabolism in renal clear cell carcinoma. , 1987, Journal of lipid research.

[25]  R. Clayman,et al.  Low density lipoprotein‐receptor activity is lost in vivo in malignantly transformed renal tissue , 1986, FEBS letters.

[26]  Jonathan J. Li,et al.  Changes in lipid profiles of estrogen‐induced and transplanted renal carcinomas in Syrian hamsters , 1983, International journal of cancer.

[27]  H. Drexel,et al.  [Lipoproteins, apolipoproteins, lipoprotein lipase, hepatic triglyceride lipase and lecithin cholesterol acyltransferase in patients with nephrotic syndrome]. , 1983, Schweizerische medizinische Wochenschrift.

[28]  K. Karlsson,et al.  The sphingolipid composition of human renal carcinoma. , 1974, Biochimica et biophysica acta.

[29]  V. Tugnoli,et al.  1H-NMR and 13C-NMR lipid profiles of human renal tissues. , 2003, Biopolymers.

[30]  M. Spraul,et al.  Magic Angle Spinning Proton Nuclear Magnetic Resonance Spectroscopic Analysis of Intact Kidney Tissue Samples , 1997 .